Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
Conclusion: Chemotherapy agents have different effects on the expression of ICP ligands in tumor cells with different pathological types, and this may affect the efficacy of combined immunotherapy. These results provide a theoretical basis for further selection and optimization of the combination of chemotherapy and immunotherapy.PMID:37728201 | DOI:10.1177/15330338231202307 (Source: Cell Research)
Source: Cell Research - September 20, 2023 Category: Cytology Authors: Yu Zhao Zhe Wang Xiuhuan Shi Ting Liu Wenwen Yu Xiubao Ren Hua Zhao Source Type: research
Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
Conclusion: Chemotherapy agents have different effects on the expression of ICP ligands in tumor cells with different pathological types, and this may affect the efficacy of combined immunotherapy. These results provide a theoretical basis for further selection and optimization of the combination of chemotherapy and immunotherapy.PMID:37728201 | DOI:10.1177/15330338231202307 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - September 20, 2023 Category: Cancer & Oncology Authors: Yu Zhao Zhe Wang Xiuhuan Shi Ting Liu Wenwen Yu Xiubao Ren Hua Zhao Source Type: research
Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
Conclusion: Chemotherapy agents have different effects on the expression of ICP ligands in tumor cells with different pathological types, and this may affect the efficacy of combined immunotherapy. These results provide a theoretical basis for further selection and optimization of the combination of chemotherapy and immunotherapy.PMID:37728201 | DOI:10.1177/15330338231202307 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - September 20, 2023 Category: Cancer & Oncology Authors: Yu Zhao Zhe Wang Xiuhuan Shi Ting Liu Wenwen Yu Xiubao Ren Hua Zhao Source Type: research
Immune checkpoint inhibitor ‐induced asthma and chronic obstructive pulmonary disease overlap in patient with adenocarcinoma
We present a case of asthma and chronic obstructive pulmonary disease overlap (ACO) induced by long-term nivolumab maintenance therapy in a patient with lung adenocarcinoma and no history of asthma. AbstractA 67-year-old current smoker Japanese man, with no history of asthma, was diagnosed with lung adenocarcinoma. He received first-line chemotherapy with carboplatin, pemetrexed, ipilimumab, and nivolumab in July 20XX-1, and subsequently a maintenance therapy with nivolumab. In October 20XX, he became aware of wheezy dyspnoea, and chest computed tomography demonstrated worsening bronchial wall thickenings. Eosinophilia was...
Source: Respirology Case Reports - September 20, 2023 Category: Respiratory Medicine Authors: Yuki Hayakawa,
Takako Kawaguchi,
Kei Yamasaki,
Miyu Endo,
Masaya Komatsu,
Yutaka Ishiguro,
Yuichi Murata,
Kazuhiro Yatera Tags: CASE REPORT Source Type: research
Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer: A Case Report
Intern Med. 2023 Sep 15. doi: 10.2169/internalmedicine.2429-23. Online ahead of print.ABSTRACTA 55-year-old man with stage IV lung adenocarcinoma was treated with cisplatin, pemetrexed, nivolumab, and ipilimumab. Approximately 100 days after treatment initiation, he became disoriented and presented to the emergency department with a high fever. Blood tests revealed liver and kidney dysfunctions. Subsequently, the patient developed generalized convulsions that required intensive care. He was clinically diagnosed with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Organ da...
Source: Internal Medicine - September 18, 2023 Category: Internal Medicine Authors: Takaaki Tanaka Masataka Taoka Go Makimoto Kiichiro Ninomiya Hisao Higo Masanori Fujii Eiki Ichihara Kadoaki Ohashi Katsuyuki Hotta Masahiro Tabata Yoshinobu Maeda Source Type: research
A multicenter, open ‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer
ConclusionCombination chemotherapy with PEM plus Bev in elderly patients with previously untreated advanced non-squamous NSCLC exhibited favorable antitumor activity and tolerability, suggesting that a combination of PEM plus Bev might be a promising treatment option for this population. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 18, 2023 Category: Cancer & Oncology Authors: Yohei Yabuki,
Masaki Hanibuchi,
Eiji Takeuchi,
Takashi Haku,
Takanori Kanematsu,
Naoki Nishimura,
Yuko Toyoda,
Atsushi Mitsuhashi,
Kenji Otsuka,
Seidai Sato,
Hisatsugu Goto,
Hiroto Yoneda,
Hirokazu Ogino,
Hiroshi Nokihara,
Shinohara Tsutomu, Tags: ORIGINAL ARTICLE Source Type: research
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006 (Source: Ann Oncol)
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research
Colitis induced by PD-1 inhibitor combined with platinum-containing dual drug chemotherapy in Lewis mice and its mechanism
CONCLUSIONS: This treatment can inhibit the growth of transplanted tumors but will cause colitis in Lewis mice. The impairment of intestinal barrier function following administration cause an imbalance in the expression of pro-inflammatory and anti-inflammatory factors in the colon, thus causing colitis.PMID:37675720 | DOI:10.4103/jcrt.jcrt_2078_22 (Source: Cancer Control)
Source: Cancer Control - September 7, 2023 Category: Cancer & Oncology Authors: Chunhai Li Lixin Wang Daqian Sun Tianxiao Yao Xiuying Xian Yufeng Cheng Source Type: research
En bloc resection of the recurrent pleural mesothelioma and reconstruction of the chest wall after immunotherapy: A case report
A 41-year-old female presented with a 6-month history of a chest wall mass detected after resection of a right pleural mesothelioma 2 years previously, and we resected the tumor and reconstructed the thoracic wall after neoadjuvant immunotherapy. AbstractMalignant pleural mesothelioma (MPM) is associated with previous asbestos exposure, while more clinical insights into this disease have come from other case studies. Maximal cytoreduction is critical in disease control and might help to improve the prognosis. Here, a 41-year-old female presented with a 6-month history of a mass detected in the chest wall following resec...
Source: Thoracic Cancer - September 2, 2023 Category: Cancer & Oncology Authors: Changlong Qin,
Qinghong Xia,
Zi ‐Jia Chen,
Qinghua Zhou,
Xi Zheng Tags: CASE REPORT Source Type: research
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer
J Clin Oncol. 2023 Sep 1:JCO2300179. doi: 10.1200/JCO.23.00179. Online ahead of print.ABSTRACTClinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The JIPANG study is an open-label phase III trial evaluating the efficacy of pemetrexed plus cisplatin (PemP) vers...
Source: Clinical Breast Cancer - September 1, 2023 Category: Cancer & Oncology Authors: Hirotsugu Kenmotsu Nobuyuki Yamamoto Toshihiro Misumi Kiyotaka Yoh Haruhiro Saito Shunichi Sugawara Koji Yamazaki Kazuhiko Nakagawa Kenji Sugio Takashi Seto Shinichi Toyooka Hiroshi Date Tetsuya Mitsudomi Isamu Okamoto Kohei Yokoi Hideo Saka Hiroaki Okamo Source Type: research
